deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04280718

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE+)

Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sponsor: argenx

Conditions Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Interventions Efgartigimod PH20 SC
Updated 28 times since 2020 Last updated: Jun 25, 2025 Started: Sep 18, 2020 Primary completion: Apr 30, 2027 Completion: Apr 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and is currently ongoing. argenx leads this study, which shows 28 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2020 – ~Sep 2020 · 6 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Jan 2023 · 6 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

28 versions recorded

  1. Dec 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Jul 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 23 earlier versions

  1. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jun 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  4. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  5. Mar 2023 — May 2023 [monthly]

    Recruiting PHASE2

  6. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  7. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  8. Jul 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  9. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  10. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  11. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  12. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  13. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  14. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  15. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  16. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  17. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  18. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  19. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  20. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  21. Oct 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE2

  22. Sep 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE2

  23. Mar 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • argenx
Data source: argenx

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Amsterdam, Netherlands , Angers, France , Austin, United States , Badalona, Spain , Barcelona, Spain , Beijing, China , Belgrade, Serbia , Birmingham, United States , Boca Raton, United States and 122 more locations